Cigna’s new plan to cowl multi-million greenback gene therapies


A display screen shows the brand fro Cigna Corp. on the ground on the New York Inventory Change (NYSE) in New York, U.S., July 16, 2019. REUTERS/Brendan McDermid

(Reuters) Well being insurer Cigna Corp on Thursday introduced a brand new program that covers prices for costly gene therapies that may reduce out-of-pocket funds for purchasers.

Spark Therapeutics Inc and Novartis AG’s blindness remedy, Luxturna, and Novartis’ $2.1 million spinal muscular atrophy remedy, Zolgensma, would be the first two gene therapies included in this system, the corporate stated.

Reporting by Manojna Maddipatla in Bengaluru; Modifying by Anil D’Silva

Author: Maxwell C.

Leave a Reply

Your email address will not be published. Required fields are marked *